Chinese Journal of Respiratory and Critical Care Medicine
Supervisor：Ministry of Education of the People's Republic of ChinaSponsor：West China Medical Center & West China Hospital, Sichuan University Editor-in-chief：LIN Jiangtao / LIU Chuntao Publishing period：
Monthly
ISSN：1671-6205CN：51-1631/R
Citation：姚秀娟, 李蘭鳳, 洪如鈞, 何毅輝, 謝寶松. 雙肺多發結節伴囊腔影. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(11): 817-820. doi: 10.7507/1671-6205.202101036Copy
Copyright ? the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved
1.
Suri HS, Yi ES, Nowakowski GS, et al. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis, 2012, 7: 16.
2.
Mourah S, How-Kit A, Meignin V, et al. Recurrent NRAS mutations in pulmonary langerhans cell histiocytosis. Eur Respir J, 2016, 47(6): 1785-1796.
Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med, 2018, 379(9): 856-868.
5.
Goyal G, Young JR, Koster MJ, et al. The Mayo clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc, 2019, 94(10): 2054-2071.
6.
Kumar A, Cherian SV, Vassallo R, et al. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest, 2018, 154(2): 394-408.
7.
Lorillon G, Tazi A. How I manage pulmonary langerhans cell histiocytosis. Eur Respir Rev, 2017, 26(145): 170070.
Obert J, Vercellino L, Van Der Gucht A, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging, 2017, 44(4): 598-610.
10.
Hazim AZ, Ruan GJ, Ravindran A, et al. Efficacy of BRAF-inhibitor therapy in BRAFV600E-mutated adult Langerhans cell histiocytosis. Oncologist, 2020, 25(12): 1001-1004.
1. Suri HS, Yi ES, Nowakowski GS, et al. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis, 2012, 7: 16.
2. Mourah S, How-Kit A, Meignin V, et al. Recurrent NRAS mutations in pulmonary langerhans cell histiocytosis. Eur Respir J, 2016, 47(6): 1785-1796.
4. Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med, 2018, 379(9): 856-868.
5. Goyal G, Young JR, Koster MJ, et al. The Mayo clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc, 2019, 94(10): 2054-2071.
6. Kumar A, Cherian SV, Vassallo R, et al. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest, 2018, 154(2): 394-408.
7. Lorillon G, Tazi A. How I manage pulmonary langerhans cell histiocytosis. Eur Respir Rev, 2017, 26(145): 170070.
9. Obert J, Vercellino L, Van Der Gucht A, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging, 2017, 44(4): 598-610.
10. Hazim AZ, Ruan GJ, Ravindran A, et al. Efficacy of BRAF-inhibitor therapy in BRAFV600E-mutated adult Langerhans cell histiocytosis. Oncologist, 2020, 25(12): 1001-1004.
Click the content below to copy and paste a set citation format。
Citation：姚秀娟, 李蘭鳳, 洪如鈞, 何毅輝, 謝寶松. 雙肺多發結節伴囊腔影. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(11): 817-820. doi: 10.7507/1671-6205.202101036
1/5
WeChat